The NYSE-listed firm said it has begun an evaluation of its Nu.QTM Colorectal Cancer Triage product in a Taiwanese population of 383 subjects
Showing 25 of 5083
Opdivo sales jumped by 60% in the three months to March
The Austin-based company was notified of a negative trend decision by the EMA
The data will be given in what's called a poster presentation in the Netherlands.
Bristol is licensing an experimental neurodegenerative disorder drug to Biogen and a Duchenne muscular dystrophy treatment to Roche
Cameron Reynolds, Volition’s chief executive, expressed confidence that Vanston would add value as VolitionRx becomes a revenue-generating company.
Dr Marc Hedrick, president and chief executive, said it was another milestone for the firm.
GBM brain cancer affects 130,000 annually with 3-5% survival rate.
Results were were close to those achieved from antidepressants on the market
The transformation of the business was reflected by top line growth of 510%
Akers will use the proceeds of its fundraising to boost capital and support the business following successful trials of new rapid diagnostic tests
The firm will show PBT434 can prevent the loss of neurons that underpin motor and cognitive dysfunction.
Shares in the drug developer added almost 40% to stand at $5.77 each
Over the past six years Vollmer Dahlke has raised over US$25mln in non-dilutive grants
The debenture holders converted all the outstanding $728,000 of debt into over 2.6mln shares and around 1.753mln share purchase warrants.
The IndyCar racing driver is serving for a second consecutive term.
First Check Diagnostics, the exclusive distributor in the US, will sell it under its "First Check" brand
Allergan intends to submit an application to the US Food & Drug Administration (FDA) in the second half of 2017.
The firm has enhanced its sales capabilities for 2017 by contracting a well-regarded life sciences lead generation service and hiring two sales directors.
The firm issued 1.575mln units as payment of $504,000, which was the total amount due under all the debentures.
VentriPoint Diagnostics shares shot up by a fifth on Wednesday after the company said it is increasing the maximum gross proceeds of its non-brokered private placement to C$3.2mln from C$2mln and will now issue up to 10 million units at 32 cents per unit
The biopharma company said it has made progress on the development of several cancer treatments
VentriPoint Diagnostics said it intends to complete a non-brokered private placement of up to 6.25mln units at 32 cents per unit for total gross proceeds of up to C$2mln
The target date for the FDA to complete its sNDA review is 6 November, 2017.
Drugs and treatment group M Pharmaceutical Inc on Monday announced that Kim Whittemore has been appointed to its board of directors